SG Americas Securities LLC bought a new position in Neurogene Inc. (NASDAQ:NGNE – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,576 shares of the company’s stock, valued at approximately $150,000.
Several other large investors also recently added to or reduced their stakes in NGNE. Vanguard Group Inc. grew its position in Neurogene by 906.5% in the first quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock worth $25,831,000 after acquiring an additional 457,062 shares in the last quarter. Integral Health Asset Management LLC bought a new stake in Neurogene in the second quarter worth approximately $2,547,000. Driehaus Capital Management LLC grew its position in Neurogene by 123.8% in the second quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company’s stock worth $3,719,000 after acquiring an additional 56,533 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Neurogene in the second quarter worth approximately $1,107,000. Finally, Avoro Capital Advisors LLC bought a new stake in shares of Neurogene during the 2nd quarter worth $802,000. 52.37% of the stock is owned by institutional investors.
Neurogene Price Performance
Shares of Neurogene stock opened at $48.20 on Friday. Neurogene Inc. has a fifty-two week low of $12.49 and a fifty-two week high of $55.21. The firm has a fifty day moving average price of $41.60 and a two-hundred day moving average price of $38.12.
Wall Street Analyst Weigh In
NGNE has been the subject of several recent analyst reports. HC Wainwright decreased their price objective on shares of Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a report on Monday, August 12th. BMO Capital Markets initiated coverage on shares of Neurogene in a report on Thursday, June 27th. They set an “outperform” rating and a $65.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Neurogene has a consensus rating of “Buy” and an average target price of $51.00.
Read Our Latest Stock Analysis on Neurogene
Neurogene Company Profile
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Articles
- Five stocks we like better than Neurogene
- How to Choose Top Rated Stocks
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Investing In Preferred Stock vs. Common Stock
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Trading Halts Explained
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding NGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurogene Inc. (NASDAQ:NGNE – Free Report).
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.